|
May 12
|
Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
May 7
|
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
|
|
Mar 12
|
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
|
|
Feb 13
|
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
|